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Honors Thesis: Removal of Carbamazepine from Drinking Water 
WERC Environmental Design Competition 2018 
 
During the spring semester of 2018, I participated on a team of six senior chemical engineering students 
to compete in the 2018 WERC Environmental Design Competition. We competed in the 5th task and 
were challenged to create an in-home unit capable of removing carbamazepine, an antiepileptic 
pharmaceutical, from wastewater. The task objective was to reduce CBZ from 1 ppm to 1 ppb while using 
no more than 1 kWh per day. We decided to design the full-scale system to treat approximately 5 gpm 
because the average household would use about that much if two showers were running simultaneously. 
 
Originally, I was tasked with researching the multitude of potential treatment options over winter break. 
Through literary research I was able to eliminate majority of the treatment options either because of the 
ineffective/inefficient removal of CBZ, cost of treatment, retention time of the process, or use of harmful 
chemicals. Some of the options that I was quickly able to rule out for the mentioned reasons were 
presented as bench-scale treatment options by some of the teams we competed against at the competition. 
My final, top 3 recommendations for viable treament options ended up being reverse osmosis, ozonation, 
activated carbon, or some combination thereof. During this time, I also recommended that my team use 
Slack, a team collaboration tool, to communicate over the course of our research and project design and to 
organize our thoughts and project assignments. Additional research was also conducted in order to 
determine the true concerns around carbamazepine. From what we found in the research, we were able to 
concluded that carbamazepine concentrations are not an immediate concern, but there could be problems 
in the future with CBZ build up in the environment because conventional wastewater treatment methods 
do not remove it. 
 
I knew it would be best if we were able to treat the water instantaneously so that there would be no need 
for a large storage reservoir and water would always be available on-demand. This way, there is no finite 
supply of water, no waiting 2 hours or so to treat the water in a batch system, and the homeowner is 
guaranteed water every time they turn on the faucet. From my experience working with start-up 
companies, I know that ease-of-installation and ease-of-use are critical for an in-home unit. Homeowners 
want to understand what is in their home and treating their water, but it would also be easy for them to 
hire an external contractor/plumber to maintain the system if need be. If we were to develop this system 
further, I would recommend having a light on the outside of the system that indicates the degree to which 
the carbon is spent. With this, the homeowner would not have to keep up with how long it has been 
between cartridge changes, and the carbon could be used to a set capacity. 
 
For the period of time where we were conducting experiments and gathering data to help narrow down 
the potential treatment options and finalize our design, I was mostly focusing on experimentation with 
ozone oxidation. Our initial experiments were batch experiments at atmospheric pressure, simply to see 
the effectiveness of ozone oxidation to reduce CBZ concentration at a reasonable rate. As expected from 
the research, ozone reacted quickly with the double bond in CBZ, and then the products from the original 
reaction were oxidized further. Once we proved the viability of ozone as an option, I determined the 
saturation point of ozone in water at the experimental conditions and made some adjustments to ensure 
that ozone was being continuously added to the system and saturating the solution. With a carbamazepine 
to ozone ratio of 6:1, I conducted further experimentation to determine the reaction rate constant. With 
this data and the first order reaction rate constant, my team was able to determine the size of the reactor 
that would be necessary to treat our full scale flow rate of 5 gpm. Through these calculations we were 
able to eliminate ozone as an option for in-home treatment for the following reasons: 1) it created by-
products with undetermined environmental and health effects 2) it was a more complicated system that 
required energy that could have potentially gone over the energy requirements 3) it was a larger system 
than some homeowners might want in their home. After the ozonation oxidation experiments, I helped to 
carry out both the batch and continuous activated carbon experiments primarily by running the HPLC to 
analyze the samples from the experiments. This was a tedious and time- consuming task, but being able to 
run the samples, analyze the results, and see the success of the experiments was extremely satisfying.  Our 
final decision, based off of the experimental work we conducted, was to use Calgon Carbon’s bituminous 
coal granular activated carbon in a series of 3 filter housings. 
 
To present our data and information, we put together a report, presentation, poster, and pamphlet. I 
worked primarily on the introductory portions of the paper, the design considerations, and experimental 
sections. I was in charge of creating the pamphlet, as well as proofreading, rewording, restructuring, and 
producing the final draft of the presentation, poster, and paper. During the competition, I was not one of 
the four team members to present, so I was able to help each presenter on their portion of the presentation. 
I wanted to ensure that they were presenting the best information to the judges in the most clear and 
concise way. During the poster presentation and peer-judging times, I was able to discuss our work with 
the judges and answer any questions they had concerning our process or design. In the end, the 
Carbamaza-clean team took home the first place prize and beat not only all the teams in our own task, but 
also Task 1. This set of groups was tasked with designing a water reclamation system for the International 
Space Station. I believe that we were able to take home the first place prize because both our full-scale 
design and the bench-scale demonstration we constructed were simple, on-demand, and economical in-
home water treatment solutions. 
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1.0 EXECUTIVE SUMMARY 
 Due to the increasing prevalence of prescription medication over the past few decades, 
pharmaceuticals have accumulated in various water sources. This has become a public health 
concern because many pharmaceuticals have limited research on the effects of chronic low-level 
exposure. According to the World’s Health Organization (WHO), traces of pharmaceuticals 
products have been reported in different water sources such as surface waters, wastewater, 
groundwater, and drinking water.[1] One pharmaceutical of interest that has been detected in 
water sources is carbamazepine. Carbamazepine (CBZ) is a common pharmaceutical prescribed 
for the treatment of seizure disorders, neuropathic pain, and various psychological disorders. It’s 
mechanism of action is “sodium channel blocking,” which is the impairment of conduction of 
sodium ions in sodium channels. This, in effect, reduces nervous-system conductivity in key 
areas related to the treated disorders mentioned above.[2]  
 Carbamazepine is also not easily biodegradable and current conventional treatment 
methods in some drinking water and wastewater facilities do not adequately remove 
carbamazepine and other pharmaceuticals from treated water. While carbamazepine is not 
federally regulated by the Environmental Protection Agency (EPA) under the Safe Water 
Drinking Act (SWDA) at this time, it does have the potential for producing adverse health effects 
in humans. Therefore, being proactive in finding ways to remove carbamazepine and compounds 
like it should be encouraged. The Carbamaza-Clean team designed a bench scale unit as well as 
an in-home treatment system using granular activated carbon (GAC) to effectively remove 
carbamazepine from water. GAC was chosen for this design because it is inexpensive and does 
not create by-products that are harmful to human health. 
 Several experiments were conducted to determine the efficiency of the removal of 
carbamazepine using two different GACs: coconut shell GAC (CSGAC) and bituminous coal 
GAC (BGAC). A packed bed column was constructed to determine if both carbons could reduce 
the concentration of carbamazepine from 1 ppm to 1 ppb or lower. The CSGAC packed bed was 
able to lower the concentration below 1 ppb at a packed bed length of 4.4 ft, while the BGAC 
only required half that (2.2 ft). Both carbons can remove carbamazepine to the desired 
concentration; however, the costs vary. An economic analysis was performed to determine the 
costs of the carbons. The CSGAC system would cost $990 for the first year and $589.68 for each 
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following year. The BGAC system would cost $639 for the first two years, and then $200 every 
two years following the initial capital investment. 
2.0 PURPOSE 
 An increase in demand for new freshwater sources has catalyzed the design for new water 
treatment technologies. Many communities typically reuse fresh water sources; however, there 
are many contaminants such as debris, microorganisms (bacteria and viruses), and 
micropollutants (pharmaceuticals, chemicals, pesticides, and hormones) that must be removed 
and treated before human consumption. Because of a lack of data, little is known about the 
potential health risks and environmental effects from chronic exposure to low concentrations of 
carbamazepine and its metabolites. Thus, more research must be conducted to understand the 
long-term implications on both human health and the environment. In addition, it is predicted 
that future regulations will encourage water treatment facilities to incorporate new treatment 
methods to remove carbamazepine and other pharmaceuticals. 
3.0 CONVENTIONAL WATER TREATMENT METHODS 
 Current conventional treatment methods in wastewater and drinking facilities do not 
adequately remove carbamazepine and other pharmaceuticals from water. These methods 
typically expose micropollutants to a series of treatment processes, including sedimentation tanks 
to remove suspended solids, activated sludge, dispersion, partition, biodegradation, and abiotic 
transformation.[3]  While many micropollutants are effectively removed mainly by adsorption on 
primary sludge, pharmaceuticals and hormone adsorption to sludge particles has proven to be 
insufficient.[4] At best, these conventional process steps are only able to remove trace amounts of 
pharmaceuticals and some of the human metabolites/transformation products in the influent may 
revert back to the parent compound during the biological treatment steps.[4] 
 Coagulation-flocculation is used for removing particulate matter, colloids, as well as 
some dissolved substances. For example, Matamoros and Salvadó evaluated micropollutant 
removal in a system that consisted of coagulation, flocculation, filtration (pulsed-bed sand 
filters), UV light lamps, and chlorination in treating secondary effluent.[5] The percent removal of 
carbamazepine was the lowest of the compounds evaluated, coming in at 2% removal.[5] There 
were varying degrees for the removal of carbamazepine in the studies that were related to plant-
specific factors such as the composition of wastewater (i.e. the mixture of micropollutants) and 
the treatment operating conditions and processes (i.e. mixing conditions, temperature, pH, etc.). 
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But, in each case, carbamazepine was consistently one of the most persistent pharmaceuticals 
studied. 
 Diclofenac and naproxen, two anti-inflammatory drugs that are also known to be highly 
persistent through traditional treatment processes, both showed sufficient elimination (~60%) 
through nanofiltration membrane treatment.[6] However, carbamazepine was retained. Membrane 
bioreactor (MBR) processes combine activated sludge biological treatment and membrane 
filtration (MF and UF). Through six studies with varying membrane and experimental 
conditions, carbamazepine was removed 24% at most.[7] This study, conducted by Trinh et al. 
(2012), had a solid retention time of 10-15 days, which is a significantly longer time than other 
removal methods that have been researched. 
4.0 CARBAMAZEPINE TREATMENT METHODS 
4.1 Activated Carbon Adsorption 
 One method that has shown improvement in carbamazepine removal over conventional 
water treatment methods is adsorption. Adsorption is the process of adhering molecules or atoms 
of a chemical species onto the surface of a sorbent either through reversible weak interactions 
(Van der Waals) or irreversible chemical bonds.[8] The adsorbent has a limited capacity for 
adsorption based on the surface area of the particle. Activated carbon is a preferred adsorbent 
due to its high surface area and low cost. Several studies have been conducted to compare the 
adsorption capacity of carbamazepine on several adsorbents. Some of the adsorbents tested 
included GAC, powder activated carbon (PAC), and hexagonal mesoporous silicate (HMS).  
 GAC is one of the materials that is used in typical cartridge filters. These filters are 
readily available, inexpensive, and come in various sizes. Not every GAC is the same and can be 
manufactured from different materials, such as coal, coconut shells, and wood. Some households 
currently use cartridge style filters to treat water in their homes, and appropriate housing and 
filters are readily available at hardware stores, e.g. Lowes or Home Depot. 
 PAC is similar to GAC in that it is activated carbon, but it has a smaller particle size, less 
than 0.1mm in diameter, and must be utilized using a different technique. In Figure 4.1, a typical 
process flow diagram of PAC is shown. It is fed as either a slurry or powder and mixed with the 
water that needs to be treated. The longer that PAC is in contact with water, the greater the 
adsorption. Some PAC can be removed by allowing the mixture to settle; however, this takes 
time and would not work in an “on demand” style water treatment for a home. This sediment 
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would also have to be removed and discarded, which is a further inconvenience to a homeowner. 
The water then must be filtered to remove the remaining PAC. Although PAC has a greater 
adsorption capacity than GAC, it introduces more steps, which makes this method less 
economically favorable.[8] 
 
Figure 4.1: PAC Process 
 Some research has been done on the adsorption of carbamazepine onto hexagonal 
mesoporous silicate HMS, SBA-15, MCM-41, and two functionalized derivatives of HMS: one 
with an amine group and one with a mercapto group. These are highly specialized materials that 
are expensive. According to Sigma-Aldrich, SBA-15 is approximately $200 for 5g. These types 
of adsorbents have capacities for absorbing carbamazepine between GAC and PAC. The m-HMS 
with the mercapto group had the next highest adsorption capacity.[9] m-HMS is not the best 
option for a home scale unit due to its high cost and because its absorptivity must be enhanced by 
modifying the original structure. 
4.2 Ozone Oxidation 
 Ozone oxidation is widely used in drinking water applications and in some wastewater 
treatment plants. Ozone can oxidize and breakdown larger molecules into smaller molecules with 
a higher affinity to biodegrade. This method is typically used to improve taste, odor, color, and 
disinfection of untreated water. Furthermore, it has been shown that ozone reacts quickly with 
the double bond in carbamazepine to yield several ozonation products. Mcdowell et al. 
conducted a study where the by-products for the ozone oxidation of carbamazepine were 
identified. The major by-products, BQM, BQD, and BaQD are depicted in the reaction 
mechanism of Figure 4.2.[10] 
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             Figure 4.2: Proposed Reaction Pathways for the Ozone Oxidation of Carbamazepine       
4.3 Reverse Osmosis 
 Reverse osmosis (RO) is an effective method of removing carbamazepine from drinking 
water. A study conducted in South Korea demonstrated that RO brought concentrations of 
carbamazepine below detectable limits.[11] However, RO is a more expensive process due to 
constant fouling, easily damaged membranes, and the production of a concentrated waste stream. 
Disposing of the retentate stream as well as maintaining the membrane system will be a 
complicated, expensive, and cumbersome effort to maintain a home scale unit. This is not 
favorable from an economic or ease-of-use standpoint.  
5.0 TASK PREMISE 
 The purpose of this task is to develop an economical, in-home solution to remove 
carbamazepine from 100 gallons per day of water. The considerations for this task are as follows: 
• Develop and test a prototype capable of treating 8 gallons of water in a two-hour period. 
• The prototype (and final full-scale design) must be able to remove carbamazepine from 
an entering concentration of 1 ppm to an exit concentration 1 ppb.  
• The full-scale design must have an energy requirement that does not exceed 1 kWh/day. 
• The resulting treated water must be safe for human consumption. 
6.0 ANALYTICAL TESTING 
 Carbamazepine is one of few pharmaceutical tested researched because it is resistant to 
water treatment methods and has limited biodegradability.[12]  The EPA method for testing 
pharmaceuticals and personal care products (PPCPs) in drinking water utilizes solid phase 
extraction followed by liquid chromatography combined with tandem mass spectroscopy (SPE 
LC/MS-MS).[12], [13], [14], [15]  
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 The samples for this testing procedure are solutions of milli-Q purified water (17.5 
MOhms) doped with carbamazepine and sucrose. Testing was conducted using a high-
performance liquid chromatograph with a photodiode array detector (HPLC-PDA) and liquid 
chromatography electrospray ionization tandem mass spectrometry (LC/ESI-MS/MS). The limit 
of detection (LOD) was calculated for both methods; the HPLC-PDA had a LOD of 172 ppb, 
while the LC/ESI-MS/MS had a LOD of 50 ppt. HPLC-PDA was the primary sample testing 
method due to ease of access and cost; however, if the limit of detection was exceeded, samples 
were analyzed using LC/ESI-MS/MS. 
6.1 Chemicals and Equipment 
 The chemicals used were carbamazepine, sucrose, and methanol purchased from Sigma-
Aldrich. The following instrumentation was used for testing in the Chemical Engineering 
laboratory: a C18 HPLC column, a HPLC PDA, nanopure water filters, analytical balances, hot 
plates and stirrers, pipettes, beakers, conical vials, methanol, acetonitrile, and trifluoroacetic acid 
(TFA). A LC/ESI-MS/MS was also utilized at the statewide mass spectroscopy facility on 
campus for samples which exceeded the limits of detection of the HPLC-PDA.  
6.2 Analytical Method 
 The method used for testing carbamazepine is an industrial standard HPLC protocol. 
Carbamazepine was measured using a 5 - 95% acetonitrile and water gradient with 0.1% TFA. 
The PDA, which calculates the absorbance of a compound based on the principles of Beer’s 
Law, was set to read at 285.5 nm because this is the maximum wavelength absorbance for 
carbamazepine [16]. Carbamazepine eluted off the HPLC column at approximately 19.5 minutes. 
6.3 Calibration Curves 
 A calibration curve was developed to determine the concentration of experimental 
samples.  Carbamazepine was initially dissolved in a 30% methanol solution due to its low 
solubility in pure water. This solution was then diluted to varying concentrations in water. 
 The standard concentrations were plotted against the area of the carbamazepine 
absorption peak from the HPLC results, and the data was fitted with a linear regression. The 
coefficient of determination (R2) was approximately one, indicating a near perfect linear 
relationship of the line to the diluted concentrations. The calibration curves in Figure 6.3A and 
Figure 6.3B were used to determine the concentrations of unknown samples. 
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Figure 6.3A: Carbamazepine Calibration Curve (1 - 10 ppm) 
                 
Figure 6.3B: Carbamazepine Calibration Curve (0.1 - 1 ppm) 
7.0 EXPERIMENTAL RESULTS AND DISCUSSION 
7.1 Ozone Oxidation Experiment 
7.1.1 Experimental Setup 
 Many studies have shown ozone to effectively degrade carbamazepine. Two experiments 
were performed at different carbamazepine concentrations to determine the rate at which it is 
degraded by ozone. The experiments were constructed by using the following equipment: a 
Microzone 300 generator, lab air supply, a 500 mL beaker, two baffles created from bent copper 
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tubes, a stirrer, a needle valve, and plastic tubing to connect the air supply to the needle valve, 
the needle valve to the ozone generator, and the ozone generator to the beaker. The experimental 
setup is shown in Figure 7.1.1. 
     
Figure 7.1.1: Ozone Experimental Setup 
 The ozone generator used for these experiments produces a maximum ozone output of 
0.3 g/hr at 6 SCFH (2.83 L/min) on ambient air. Using Henry’s Law as an estimation for this 
open system, the concentration of ozone soluble in 500 mL of water was determined to be about 
8.85 μmol O3/L water. The ozone specifications from both experiments are shown in Table 7.1.1. 
Table 7.1.1: Ozone Specifications 
Production rate of ozone (gO3/hr) 0.3 
Air flow rate (L/min) 2.83 
Weight percent of ozone based on air at 23℃ 0.148% 
Mole percent of ozone based on air at 23℃ 0.0893% 
Amount of ozone in air (mg O3/L air) 1.77 
Solubility ratio of O3 gas volume to O3 liquid volume soluble in water at 20℃ 
and 1 atm 
0.24 
Amount of ozone dissolved in water (mg O3/L water) 0.425 
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Concentration of ozone dissolved in 500 mL water (μmol O3/L water) 8.85 
Ozone generator power consumption (kW) .3 
7.1.2 Ozone Oxidation Procedure and Results 
The two experiments were performed at ambient temperature (23-25℃) and at 
atmospheric pressure (1 atm). For the first experiment, a 500 mL water solution of 12.107 ppm 
carbamazepine and 250 ppm sucrose was ozonated. Samples were taken at time zero and at 1/2, 
1, 3, 5, 10, 15, 25, 45, 60, and 120 minutes after the experiment had started. An HPLC was used 
to determine the concentrations of each sample. Figure 7.1.2 below shows the change in 
concentration of carbamazepine over time for the first experiment.  
 
Figure 7.1.2 Concentration of Carbamazepine vs Time for First Experiment 
From this data, it took 45 minutes for the ozone to decrease the concentration of 
carbamazepine to about 0.0190 ppm (19.0 ppb), which is about 99.8% conversion. The problem 
that emerged with the first experiment was that the concentration of ozone soluble in water (8.85 
μmol O3/L water) was too low to decrease the concentration of carbamazepine (51.243 μmol 
carbamazepine/L water) at a reasonable rate. The molar ratio of carbamazepine to ozone in water 
was nearly 6:1. As a result, this prolonged the degradation of carbamazepine. Since the solubility 
of ozone in water increases with increasing pressure, a potential solution was to perform the 
experiment again at a higher pressure. However, the solution chosen for the second experiment 
was to maintain the same process but decrease the concentration of carbamazepine to 1ppm (4.23 
μmol carbamazepine/L water). This changed the molar ratio of carbamazepine to ozone to 
approximately 1:2 and increased the degradation rate. 
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For the second experiment, the 500 mL water solution had 0.999 ppm carbamazepine and 
25 ppm sucrose. Samples were taken at time zero and at 1/2, 1, 2, 3, 5, 7, 10, 15, 20, 40, and 60 
minutes after the experiment had started. The change in carbamazepine concentration over time 
for the second experiment is shown in Figure 7.1.3. 
 
Figure 7.1.3: Concentration of Carbamazepine vs Time for Second Experiment 
In contrast to the first experiment, it took only 7 minutes for the ozone in the second 
experiment to decrease the concentration of carbamazepine to about 0.0154 ppm (15.4 ppb), 
which is about 98.5% conversion.  Further analysis of the data from both experiments concluded 
that the reaction was first order with respect to carbamazepine; however, the reaction order with 
respect to ozone could not be experimentally determined because it could not be measured. 
Mcdowell et al. concluded in a study that the reaction was first order in respect to both 
carbamazepine and ozone.[10]  
To formulate a rate expression for each experiment with respect to the concentrations of 
carbamazepine and ozone, it was assumed that the ozone concentration was constant because 
ozone was continuously generated and saturating the solution. Thus, the reaction was zero order 
in respect to ozone. From this assumption, the overall reaction rate expression and rate constant 
for the first experiment was as follows: 
𝑟 = 0.1354[𝐶𝐵𝑍]  
𝑚𝑜𝑙
𝐿 ∗ 𝑚𝑖𝑛
                        𝑘 = 0.1354 
1
𝑚𝑖𝑛
                     (7.1.1) 
The overall reaction rate expression and rate constant for the second experiment was as follows: 
𝑟 = 0.5867[𝐶𝐵𝑍]  
𝑚𝑜𝑙
𝐿 ∗ 𝑚𝑖𝑛
                        𝑘 = 0.5867 
1
𝑚𝑖𝑛
                     (7.1.2) 
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Below, Figure 7.1.4 depicts the first order test for the second experiment. The same process was 
used for the first experiment.  
 
Figure 7.1.4: First Order Test for Second Experiment 
Although ozone quickly degrades carbamazepine, when a plug flow reactor was modeled, 
the necessary volume for the desired conversion was too large for an at-home application. 
7.2 Carbon Loading Experiment 
7.2.1 Experimental Setup 
Another possible solution for removing carbamazepine from drinking water is by using 
activated carbon filters. Activated carbon can be produced from a variety of materials, including 
wood, charcoal, and coconut shells. With a global abundance of the raw materials needed to 
make activated carbon, it is readily available and fairly inexpensive.[17] To determine if activated 
carbon is effective in adsorbing carbamazepine, two different carbons were studied. The first 
carbon to be evaluated was coconut shell granular activated carbon (CSGAC) from replacement 
water filter. This carbon was chosen because it is cheap, easy to purchase, and was listed at being 
effective for pharmaceutical removal. The alternative carbon tested was bituminous coal granular 
activated carbon (BGAC), which was also listed as being effective at removal of pharmaceuticals 
from aqueous solutions. For both carbons, rates of adsorption, max adsorption of carbamazepine, 
and effects of sucrose on adsorption rates were experimentally determined. Scanning electron 
microscope images of both carbons are included below. The difference in porosity and surface 
area between the two carbons can be clearly seen in these images. Due to these physical 
attributes, BGAC was expected to outperform CSGAC.   
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Figure 7.2.1 Scanning Electron Microscope Images of CSGAC (left) and BGAC (right). 
The adsorption properties of both carbons were experimentally determined using a batch 
system with a specified amount of carbon. A solution of carbamazepine and sucrose in a 1 L 
beaker was placed on a stir plate, and a stir bar was added to mix the solution. For each 
experiment, a water sample was taken before activated carbon was added to measure the initial 
concentration. Once the experiment was running, samples were taken at designated times to 
determine the change in carbamazepine concentration over time. The experimental setup is 
shown in Figure 7.2.1. 
 
Figure 7.2.1 GAC Batch Adsorber 
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7.2.2 Carbon Loading Procedure and Results 
To determine if CSGAC adsorbs carbamazepine effectively, a batch process was 
conducted. For this experiment, two 1 L solutions of 1 ppm carbamazepine were created. 
However, one solution contained 25 ppm sucrose, while the other did not have any sucrose. This 
was done to determine the effects of sucrose on carbamazepine adsorption. Once the mixture 
reached uniformity, a sample was taken to determine the initial concentration. Then, 2.5g of 
CSGAC was added to each batch process. After the addition of the CSGAC, samples were taken 
at 5, 10, 20, 40, 60, and 120 minutes. A pseudo-first and second order rate model were created to 
relate the adsorption rates of different carbamazepine solutions. It is important to note that for 
low concentrations of carbamazepine, the equilibrium concentration adsorbed to the GAC, 𝑞𝑒,  
can be assumed to be zero. In addition, 𝑞𝑡 is the amount adsorbed to carbon at time t, and k is the 
rate constant. The rate constants for the pseudo-first order can be found by using the equation 
given by Langergen and Svenska[18]:  
ln(𝑞𝑒 − 𝑞𝑡) = ln(𝑞𝑒 − 𝑘𝑡)       (7.2.1) 
𝑞𝑒 =
[𝐶𝐵𝑍]𝑖𝑛𝑡−[𝐶𝐵𝑍]𝑒𝑞
𝑚𝑐𝑎𝑟𝑏𝑜𝑛
      (7.2.2)   
For Low Starting Concentrations [CBZ]eq~0   (7.2.3) 
𝑞𝑒 =
[𝐶𝐵𝑍]𝑖𝑛𝑡
𝑚𝑐𝑎𝑟𝑏𝑜𝑛
     (7.2.4) 
𝑞𝑡 =
[𝐶𝐵𝑍]𝑖𝑛𝑡 − [𝐶𝐵𝑍]𝑡
𝑚𝑐𝑎𝑟𝑏𝑜𝑛
     (7.2.5) 
𝑙𝑛
[𝐶𝐵𝑍]𝑡
𝑚𝑐𝑎𝑟𝑏𝑜𝑛
= 𝑙𝑛
[𝐶𝐵𝑍]𝑖𝑛𝑡
𝑚𝑐𝑎𝑟𝑏𝑜𝑛
− 𝑘𝑡   (7.2.6) 
𝑙𝑛[𝐶𝐵𝑍]𝑡 = 𝑙𝑛[𝐶𝐵𝑍]𝑖𝑛𝑡 − 𝑘𝑡      (7.2.7) 
As seen in Figure 7.2.2, the model demonstrated a strong relation with pseudo-first order 
kinetics, producing an 𝑅2 value of 0.999 and 0.994 for the sucrose and without sucrose solutions, 
respectively. By graphing equation 7.2.7, using experimental data, the rate constant can be found 
by determining the slope of the line of best fit. The difference between the rates is statistically 
insignificant- supporting the fact that sucrose, especially at low concentrations, has little effect 
on the adsorption rates. 
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Figure 7.2.2: Pseudo-First Order Kinetics of a 1 ppm Carbamazepine and CSGAC Solution 
To evaluate the relative adsorption capabilities of the CSGAC, BGAC was also tested. 
Once again, two batch processes were created to test the effectiveness of the BGAC, and the 
effects of sucrose on adsorption. Two 10 ppm carbamazepine solutions were created, while one 
contained 250 ppm sucrose and the other did not contain sucrose. As seen in Figure 7.2.3, the 
sucrose once again had minimal effect on carbamazepine adsorption. Furthermore, the rate 
constants produced by the BGAC were almost twice as high as those from the CSGAC. 
  
Figure 7.2.3: Pseudo-First Order Kinetics of a 10 ppm Carbamazepine BGAC Solution 
For the final batch experiment, the total loading or loading capacity of the BGAC (mg 
CBZ/g carbon) was determined by using higher initial concentrations and allowing the system to 
approach equilibrium. Because of the higher concentrations used in this series of experiments, 
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the final concentration of carbamazepine could not be assumed to be zero and the full pseudo-
first order equation given by Langergen and Svenska must be used.[18]  
ln(𝑞𝑒 − 𝑞𝑡) = ln(𝑞𝑒 − 𝑘𝑡)       (7.2.8) 
Two experiments were conducted to establish the maximum amount of carbamazepine 
that BGAC adsorbs. The starting concentrations were 20 ppm and 100 ppm carbamazepine. The 
20 ppm solution was able to adsorb to levels near detection limits, indicating that it was not fully 
loaded. The 100 ppm was able to reach an equilibrium concentration of 34 ppm, which is a 
capacity of 264 (mg CBZ/g carbon). Additionally, the rate equations continued to demonstrate a 
rate constant of 0.003 1/min. 
 
Figure 7.2.4: Pseudo-First Order Kinetics of a 20 ppm and 100 ppm Carbamazepine BGAC 
solution, with proportional concentrations of sucrose. 
7.3 Packed Bed Experiment 
7.3.1 Experimental Setup 
 The CSGAC and the BGAC were further tested in a packed bed to determine how 
effectively they removed carbamazepine at the maximum water flux generally achieved by a 
home GAC unit (based on 5 gallons per minute flowing through a 4 inch diameter filter). A 
diameter of 4 inches was chosen as the reference diameter because it is a common diameter for 
home-use filter housings. Based on this diameter and flow rate, an equivalent flux of 150 gpm/ft2 
for a bench scale system was achieved by using a 1 inch diameter bed flowing at 0.35 gpm. Six, 
1inch ID beds were constructed out of PVC; four were packed with CSGAC and two were 
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packed with BGAC. The experimental setup is shown in Figure 7.3.1 and as a PFD in 7.3.2 
below. 
 
Figure 7.3.1: GAC Packed Bed Experimental Setup 
 
Figure 7.3.2 Packed Bed Process Flow Diagram 
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7.3.2 Packed Bed Procedure and Results 
A stock solution (1 ppm carbamazepine, 25 ppm sucrose, using Milli-Q water) was 
created and placed into a five gallon feed tank where a sample of untreated water was taken for 
analysis. Untreated water was then pumped from the feed tank through the packed bed, and 
allowed to come to steady-state by passing 3 bed volumes of feed through the bed, and then 
sampled for analysis. Pressure and flow rate were monitored and controlled by altering the 
positions of both the feed and return valves to maintain the desired flux. This process was 
repeated for all six beds. After running each bed, the bed was detached and replaced by a new 
bed. The percent removal-results of each packed bed are shown below in Figure 7.3.3. 
 
Figure 7.3.3: Length of Packed Bed Vs. Percent Removal for Carbamazepine 
From this data, it is evident that the BGAC outperformed CSGAC at removing 
carbamazepine from feed water at the given conditions. In fact, CSGAC required approximately 
twice the volume of carbon to achieve the same removal. However, both carbons are effective at 
removing 99.9% of carbamazepine with negligible pressure drop. In addition, both carbons do 
not require an unreasonable amount of carbon to achieve the desired concentration.  
8.0 BENCH SCALE PROCEDURE 
1) Open all valves.  
2) Turn on pump.  
3) Adjust flow back valve to achieve desired flow rate.  
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4) Ensure influent tank has ample water. 
9.0 INDUSTRIAL SCALE DESIGN 
 9.1 Ozone Oxidation Scale Up 
    To design a plug flow reactor (PFR) for ozone oxidation of carbamazepine, the kinetics from 
the second ozone experiment were used. To reiterate, the rate expression obtained from this 
experiment was as follows: 
𝑟 = 0.5867[𝐶𝐵𝑍]  
𝑚𝑜𝑙
𝐿 ∗ 𝑚𝑖𝑛
                        𝑘 = 0.5867 
1
𝑚𝑖𝑛
                     (9.1.1) 
To estimate the volume of the plug flow reactor, perfect radial mixing, steady-state and constant 
density were assumed. The following equation was used to determine the volume of the PFR: 
 𝑉 = ∫
𝐹𝐴𝑜𝑑𝑋
−𝑟𝐴
= 𝐹𝐴𝑜 ∫
𝑑𝑋
𝑘𝐶𝐴
= 𝐹𝐴𝑜 ∫
𝑑𝑋
𝑘𝐶𝐴𝑜(1−𝑋)
=
−𝐹𝐴𝑜
𝑘𝐶𝐴𝑜
(ln(1 − 𝑋))
𝑋
0
𝑋
0
𝑋
0
     (9.1.2) 
Below, Table 8.1 lists the specifications used to solve for the volume of the PFR. 
Table 8.1: Industrial Scale Plug Flow Reactor Specifications 
Volumetric flow rate, vo (gal/min) 5 
Initial concentration of CBZ (ppm) 1 
Inlet flow rate of CBZ (mol/min) 8.006*10-5 
Rate constant (1/min) 0.5867 
Conversion (%) 99.9 
 
Using these values, the plug flow reactor volume needed for ozone oxidation of carbamazepine 
is 222.84 L (~223 L). POLYMATH was used to verify if the obtained volume was correct, and 
using this program, the volume of the plug reactor was calculated to be 223.64 L. The plug flow 
reactor volume for ozone oxidation a scale-up would be too large with the given criteria; thus, 
ozone oxidation was not chosen for a home scale unit. 
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 9.2 Activated Carbon Adsorption Scale Up 
 
Figure 9.2.1 Home Unit Process Flow Diagram 
The scaled-up home unit will be installed into the water inlet line to a house allowing for 
whole home filtration. To maintain water pressure in the house when filters are being changed, a 
bypass line can be opened before the filter is blocked in. The typical lines in a house a ¾” copper 
tubing and will require 2 reducer bushings to connect to the 1” connections on the filter housing. 
10.0 ECONOMIC ANALYSIS 
Using the results from the carbon loading experiments, a Freundlich Isotherm was 
developed using the equation below. Ce is the equilibrium concentration in solution in (mg/L), qe 
is the mass adsorbed/mass of carbon in (mg/g), and Kf and 1/n are the Freundlich constants. 
𝑞𝑒 = 𝐾𝑓𝐶𝑒
1/𝑛
      (10.1.1) 
Table 10.1 Activated Carbon Capacities 
 
BGAC CSGAC 
Kf (mg/g)(L/mg)1/n 17.52 4.301 
1/n 0.5235 0.5887 
Capacity at 1 ppm  (mg/g) 17.52 4.301 
Carbon use per year (lb/yr) 17.37 70.75 
 
The isotherms, in Table 10.1 above, indicate that the BGAC has a capacity four times greater 
than the CSGAC. As a result, less carbon is required to reduce the carbamazepine concentration 
to 1 ppb. The isotherms are limited, though, since they are not accounting for the linear portion 
of the adsorption curve and true equilibrium. By not using final equilibrium data, the value of 
carbon capacity will be underestimated; however, it will ensure that the filters stay in a state 
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where they readily absorb carbon.  Ultimately, basing the life of the filters on these models will 
provide a conservative estimate that could be further refined with more data. 
     Both types of carbon require the same system setup and will have similar costs. The 
housing system costs $250 for three 20”x4.5” housings and bracket. Differences in cost would be 
the cost of the filters and the frequency at which they must be replaced. A CSGAC cartridge 
holds approximately 4lbs of carbon, so the total housing capacity would be 12lbs. From the data 
in Table 10.1, the filters would need to be replaced every 2 months at a yearly cost of $589.68. 
The BGAC does not come in prebuilt units and requires different steps than the CSGAC 
cartridge. Because the carbon casing must be emptied and refilled, the replacement of carbon 
will be more hands on than simply replacing an entire CSGAC cartridge. Three refillable casings 
are required for BGAC and can hold 6lbs of carbon each. This brings the total amount of carbon 
to 18lbs and could sustain removal for a year before needing to be replaced. A 35lb bag of 
BGAC costs $180 and will last 2 years; that is $90 a year to maintain the unit.  
In total, the CSGAC system would cost $990 for the first year and $589.68 for each 
following year. The BGAC system would cost $639 for the first two years, and then $200 every 
two years following the initial capital investment. 
11.0 HEALTH AND ENVIRONMENTAL CONCERNS 
     Although research has been conducted over the past decade on concentration levels of 
various pharmaceuticals in source water and drinking water, there is limited data to determine 
the potential health risks. The WHO concluded from three case studies that even though 
pharmaceuticals, such as carbamazepine, are detected in drinking water, concentration levels 
(even at the highest reported concentration) are 1000 fold below the acceptable daily intake 
(AID) or minimum therapeutic dose (MTD).[1] Currently, the EPA has not implemented 
regulations of carbamazepine. The general public is not adequately informed of possible health 
effects from carbamazepine; thus, there is a concern for sensitive populations such as people who 
have allergies, people who take drugs that cannot be mixed with other drugs, pregnant women, 
children, and elders.[19] 
     Public health is not the only concern; the environment is also affected by the presence of 
carbamazepine in source water and drinking water if the concentration of carbamazepine were to 
exceed the MTD. Water contaminated with carbamazepine used for industrial purposes, such as 
farming, can reach other organisms. A study, conducted by Franklin et al., showed that wheat 
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grain did contain carbamazepine; however, the concentration was considerably low (ng/g) to 
cause a potential health threat. Furthermore, carbamazepine was most likely accumulated during 
its maturity stage.[20] Another study, performed by Dordio et al., showed that a metabolite of 
carbamazepine was present in Typha plants. Dordio et al., proposed that the presence of the 
metabolite exemplifies that degradation of carbamazepine occurs within the plant during its 
development stage. This proposal could explain why the wheat grain and typha plants contained 
a low concentration of carbamazepine. The accumulation of carbamazepine in these plants could 
also be due to lack of moisture in their maturity stage.[20],[21] From these studies, it is important to 
consider future removal of carbamazepine to mitigate human health and environmental effects. 
12.0 REGULATIONS AND FUTURE IMPACTS 
Currently, there are no EPA regulations on carbamazepine levels in drinking water or 
wastewater treatment plants. However; regulations have been implemented in Minnesota. The 
Minnesota Department of Health set a guidance value of 40 ppb for drinking water, which is 
significantly greater than the concentration of carbamazepine reported in various water 
sources.[22] While there are no country wide regulations today, it is believed that there will be 
regulations put in place in the next few years.  
If regulations are enacted in the future to demand drinking water facilities to remove 
carbamazepine, there can be an impact on the capability of companies meeting the requirements 
depending on how low the concentration limit is set.  Larry Lloyd, PE., the Chief Operating 
Officer from the Beaver Water District facility in Lowell, AR, was asked on the future 
implications of pharmaceutical regulations. From Lloyd’s statement, drinking water facilities 
could potentially not meet the requirements since it would be costly to implement treatment 
methods if only a small percentage of treated water is used for human consumption. If drinking 
water facilities do implement new treatment methods, it could be possible that the water bill for 
homeowners will increase, so facilities could cover the costs of the added treatment methods.  
Another future implication from the implementation of regulation could be how 
contaminated water is treated. Ozone oxidation does degrade carbamazepine, however, the 
effects of the by-products are not known. This a health concern since the by-products could be 
more harmful than carbamazepine. If future regulations are implemented, water treatment 
facilities will have to consider the potential health effects of by-products formed in certain 
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treatment methods. Granular activated carbon is an ideal removal method because degradation 
products are not produced. 
13.0 CONCLUSIONS AND RECOMMENDATIONS 
Before regulations are enacted, more research on the potential health effects of 
carbamazepine must be conducted. Once regulations have been implemented, water treatment 
facilities will have to remove carbamazepine without endangering consumers from harmful by-
products and without affecting the facility and consumers economically. Lloyd proposed that a 
potential solution would be for drinking water facilities or local stores, such as Lowes or Home 
Depot, to sell home units that are adequately designed to remove pharmaceuticals. This solution 
would demand an upfront cost for consumers and occasional maintenance costs; however, there 
could be economic incentives as it would prevent an increase in treatment costs at the plant. 
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